Literature DB >> 17188801

Risk-adjusted analysis of positive surgical margins following laparoscopic and retropubic radical prostatectomy.

Karim Touijer1, Kentaro Kuroiwa, James A Eastham, Andrew Vickers, Victor E Reuter, Peter T Scardino, Bertrand Guillonneau.   

Abstract

OBJECTIVES: To prospectively compare in a contemporary and contemporaneous series the positive surgical margin (PSM) rate between laparoscopic (LRP) and retropubic (RRP) radical prostatectomy at the same institution.
METHODS: Between 1 January 2003 and 30 June 2005, 1177 consecutive men with clinically localized adenocarcinoma of the prostate underwent radical prostatectomy at the same institution: 485 laparoscopically and 692 through a retropubic approach. Partin table probability of organ-confined (OC) disease was used as an index of disease aggressiveness: The PSM rate between the two approaches was compared, with adjustment for the OC probability.
RESULTS: Overall both surgical approaches had a comparable PSM rate of 11.3% after LRP and 11% after RRP. In a logistic regression analysis adjusting for OC probability, there was no statistically significant difference between LRP and RRP (odds ratio [OR]: 1.156; 95% confidence interval [%95 CI], 0.792, 1.686; p=0.5). There was a statistically significant decrease over time in the rate of PSM for LRP (OR: 0.71 per 100 patients treated; %95 CI, 0.57, 0.89; p=0.003), while that of RRP was unchanged (OR: 1.06 per 100 patients treated; %95 CI, 0.94, 1.21; p=0.3; p=0.002 for interaction between change over time and procedure).
CONCLUSIONS: In our institution, laparoscopic and retropubic radical prostatectomy provide comparable PSM rates for patients with clinically localized prostate cancer. The PSM rate over the study period remained unchanged in the RRP experience, indicating a mature and well-established operative technique, while that of LRP underwent a significant decrease, demonstrating that the procedure and therefore the results continued to evolve during the study.

Entities:  

Mesh:

Year:  2006        PMID: 17188801     DOI: 10.1016/j.eururo.2006.12.014

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  7 in total

1.  A multi-institutional comparison of radical retropubic prostatectomy, radical perineal prostatectomy, and robot-assisted laparoscopic prostatectomy for treatment of localized prostate cancer.

Authors:  Eric E Coronato; Justin D Harmon; Phillip C Ginsberg; Richard C Harkaway; Kulwant Singh; Leonard Braitman; Bruce B Sloane; Jamison S Jaffe
Journal:  J Robot Surg       Date:  2009-10-01

Review 2.  Is laparoscopy dying for radical prostatectomy?

Authors:  Xavier Cathelineau; Rafael Sanchez-Salas; Eric Barret; François Rozet; Guy Vallancien
Journal:  Curr Urol Rep       Date:  2008-03       Impact factor: 3.092

3.  Patient reported functional outcomes following robotic-assisted (RARP), laparoscopic (LRP), and open radical prostatectomies (ORP).

Authors:  G J Nason; F O'Kelly; S White; E Dunne; G P Smyth; R E Power
Journal:  Ir J Med Sci       Date:  2016-10-28       Impact factor: 1.568

Review 4.  [Robot-assisted surgery in urology].

Authors:  G J Wirth; J Hauser; A Caviezel; J Schwartz; N Fleury; S-N Tran; C E Iselin
Journal:  Urologe A       Date:  2008-08       Impact factor: 0.639

5.  Laparoscopic extraperitoneal radical prostatectomy: impact of the learning curve on perioperative outcomes and margin status.

Authors:  Alejandro R Rodriguez; Kapoor Rachna; Julio M Pow-Sang
Journal:  JSLS       Date:  2010 Jan-Mar       Impact factor: 2.172

6.  Frequency of positive surgical margin at prostatectomy and its effect on patient outcome.

Authors:  Kenneth A Iczkowski; M Scott Lucia
Journal:  Prostate Cancer       Date:  2011-06-09

7.  Determinants and effects of positive surgical margins after prostatectomy on prostate cancer mortality: a population-based study.

Authors:  Valesca P Retèl; Christine Bouchardy; Massimo Usel; Isabelle Neyroud-Caspar; Franz Schmidlin; Gregory Wirth; Christophe Iselin; Raymond Miralbell; Elisabetta Rapiti
Journal:  BMC Urol       Date:  2014-11-05       Impact factor: 2.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.